



165 – 10551 Shellbridge Way  
Richmond, BC, V6X 2W8

## **BIOMARK CONTRIBUTES ADDITIONAL SCIENTIFIC PUBLICATION**

**Vancouver, British Columbia – (March 14<sup>th</sup>, 2019)** – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal *Future Science OA*.

Rashid Ahmed, President and CEO, says, “This is our follow up publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides further scientific validation and evidence that one of our technology platforms (SSAT1 assay) has important clinical applications in the cancer diagnostic space. We believe that the SSAT1 assay platform is robust and can be leveraged to detect other cancer types. Potential utility of the assay includes being used as a surveillance test in populations at high risk for developing cancer and for monitoring patients after surgical or chemo/radiation therapy to detect not only the response of the tumor to the intervention, but also the possibility to detect the proliferation of new cancer cells.”

“BioMark is looking forward to publishing additional peer reviewed papers and present abstracts or posters in the near term on significant discoveries that it has invested resources over the past few years.” says Rashid.

The paper is available through open access at <https://www.future-science.com/doi/full/10.4155/fsoa-2018-0106>. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

### **About Future Science OA**

Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery, delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold open access journal, *Future Science OA*, also embraces the importance of publishing all good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health.

## Future Science Journals

Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge information on the most exciting emerging trends in their field of endeavour.

Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for more information, see [Subscriptions and Pricing](#)).

Contact:

[Laura Dormer](#), Editorial Director

Future Science Group,  
Unitec House,  
2 Albert Place,  
London,  
N3 1QB, UK

### **About BioMark Diagnostics Inc.**

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website <https://thecse.com/>.

### **For further information on BioMark, please Contact:**

Rashid Ahmed Bux  
President & CEO  
BioMark Diagnostics Inc.  
Tel. 604-370-0779  
Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

**The CSE has not reviewed, approved or disapproved the content of this press release.**